Cleveland Clinic now offers an advanced genomic testing platform as standard of care to patients with cancer. This expanded capability allows turns cancer treatment into a “stealth bullet” that allows clinicians to identify genetic defects and connect patients with individualized, lifesaving therapies.
Adult patients with pathologic stage III or IV head and neck squamous cell carcinoma (HNSCC) are being sought for a prospective clinical study. Cleveland Clinic is one of 237 locations nationwide where the prospective, randomized, Phase III trial focused on adjuvant therapy is being conducted.
Many cancers with higher mortality rates and high incidence are underfunded, including colorectal, lung, hepatobiliary and uterine cancers.
These guidelines underscore the idea that standardization in tissue collection and processing can better support reproducible studies of antitumor immunity.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
With more than 80 experts, Cleveland Clinic Cancer Center’s Rare Cancers and Blood Diseases Initiative provides advanced care and access to clinical trials for patients with novel malignancies.
The science of cancer care is advancing at a rapid place, contributing to improvements in the survival of pediatric and older adult patients with cancer. But adolescents and young adults are not seeing the same outcomes, perhaps in part due to their low enrollment rates in cancer clinical trials. Hematologist-oncologist Stefanie Thomas, MD, explains.
Two related Cleveland Clinic studies examining acute myeloid leukemia outcomes in various patient populations bolster the case for easing some restrictions on clinical trial enrollment, which could increase access for patients who potentially could benefit and produc less racially biased, more generalizable results.
Cleveland Clinic has a number of active clinical trials to investigate head and neck cancers. Learn more about open studies, inclusion criteria and more.
Cancer patients whose clinical trial participation helps drug makers commercialize new therapies shouldn’t have to pay for those lifesaving drugs, an oncologist argues.
Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies